Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Novel PET Tracers in the Management of Cardiac Sarcoidosis

Author(s): Alberto Miceli*, Stefano Raffa, Maria Isabella Donegani, Vanessa Cossu, Silvia Morbelli, Cecilia Marini, Gianmario Sambuceti and Matteo Bauckneht

Volume 14, Issue 3, 2021

Published on: 02 June, 2020

Page: [220 - 227] Pages: 8

DOI: 10.2174/1874471013666200602145418

Price: $65

Abstract

Sarcoidosis is a systemic inflammatory disease of unknown etiology, pathologically characterized by non-caseating granulomas involving several organs and tissues. This pathological process can eventually affect the heart during his course leading to fibrosis associated with systolic dysfunction, conduction disturbance, and even sudden cardiac death. Due to this prognostic impact, diagnosis is crucial to optimize clinical management. The low sensitivity of endomyocardial biopsy and its invasive nature prevents its application as a first-line diagnostic approach. Thus, several efforts have been dedicated to the identification of advanced imaging tools for the diagnosis and monitoring of cardiac involvement in systemic sarcoidosis, including Positron Emission Tomography (PET). Starting from strengths and disadvantages of 18F-Fluorodeoxyglucose (18F-FDG) PET imaging, the present narrative review will summarize state of the art and future perspectives about radiotracers other than 18F-FDG of potential interest in the field of CS, including somatostatin receptor- ligands, proliferation markers and hypoxia displaying agents.

Keywords: Cardiac sarcoidosis, positron emission tomography, fluorodeoxyglucose, dotapeptides, proliferation, hypoxia.

« Previous Next »
Graphical Abstract

[1]
Hulten, E.; Aslam, S.; Osborne, M.; Abbasi, S.; Bittencourt, M.S.; Blankstein, R. Cardiac sarcoidosis-state of the art review. Cardiovasc. Diagn. Ther., 2016, 6(1), 50-63.
[PMID: 26885492]
[2]
Roberts, W.C.; McAllister, H.A., Jr; Ferrans, V.J. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am. J. Med., 1977, 63(1), 86-108.
[http://dx.doi.org/10.1016/0002-9343(77)90121-8] [PMID: 327806]
[3]
Matsui, Y.; Iwai, K.; Tachibana, T.; Fruie, T.; Shigematsu, N.; Izumi, T.; Homma, A.H.; Mikami, R.; Hongo, O.; Hiraga, Y.; Yamamoto, M. Clinicopathological study of fatal myocardial sarcoidosis. Ann. N. Y. Acad. Sci., 1976, 278(1), 455-469.
[http://dx.doi.org/10.1111/j.1749-6632.1976.tb47058.x] [PMID: 1067031]
[4]
Silverman, K.J.; Hutchins, G.M.; Bulkley, B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation, 1978, 58(6), 1204-1211.
[http://dx.doi.org/10.1161/01.CIR.58.6.1204] [PMID: 709777]
[5]
Cooper, L.T.; Baughman, K.L.; Feldman, A.M.; Frustaci, A.; Jessup, M.; Kuhl, U.; Levine, G.N.; Narula, J.; Starling, R.C.; Towbin, J.; Virmani, R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the american heart association, the american college of cardiology, and the european society of cardiology endorsed by the heart failure society of america and the heart failure association of the european society of cardiology. Eur. Heart J., 2007, 28(24), 3076-3093.
[http://dx.doi.org/10.1093/eurheartj/ehm456] [PMID: 17959624]
[6]
Genovesi, D.; Bauckneht, M.; Altini, C.; Popescu, C.E.; Ferro, P.; Monaco, L.; Borra, A.; Ferrari, C.; Caobelli, F. The role of positron emission tomography in the assessment of cardiac sarcoidosis. Br. J. Radiol., 2019, 92(1100), 20190247.
[http://dx.doi.org/10.1259/bjr.20190247] [PMID: 31166768]
[7]
Birnie, D.H.; Sauer, W.H.; Bogun, F.; Cooper, J.M.; Culver, D.A.; Duvernoy, C.S.; Judson, M.A.; Kron, J.; Mehta, D.; Cosedis Nielsen, J.; Patel, A.R.; Ohe, T.; Raatikainen, P.; Soejima, K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm, 2014, 11(7), 1305-1323.
[http://dx.doi.org/10.1016/j.hrthm.2014.03.043] [PMID: 24819193]
[8]
Banba, K.; Kusano, K.F.; Nakamura, K.; Morita, H.; Ogawa, A.; Ohtsuka, F.; Ogo, K.O.; Nishii, N.; Watanabe, A.; Nagase, S.; Sakuragi, S.; Ohe, T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm, 2007, 4(10), 1292-1299.
[http://dx.doi.org/10.1016/j.hrthm.2007.06.006] [PMID: 17905334]
[9]
Futamatsu, H.; Suzuki, J.; Adachi, S.; Okada, H.; Otomo, K.; Ohara, T.; Hashimoto, Y.; Kakuta, T.; Iesaka, Y.; Yamaguchi, H.; Sakurada, H.; Sato, A.; Obayashi, T.; Niwa, A.; Hirao, K.; Isobe, M. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int. J. Cardiovasc. Imaging, 2006, 22(3-4), 443-448.
[http://dx.doi.org/10.1007/s10554-005-9043-x] [PMID: 16763884]
[10]
Youssef, G.; Leung, E.; Mylonas, I.; Nery, P.; Williams, K.; Wisenberg, G.; Gulenchyn, K.Y.; Dekemp, R.A.; Dasilva, J.; Birnie, D.; Wells, G.A.; Beanlands, R.S. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J. Nucl. Med., 2012, 53(2), 241-248.
[http://dx.doi.org/10.2967/jnumed.111.090662] [PMID: 22228794]
[11]
Bauckneht, M.; Ticconi, F.; Piva, R.; Slart, R.H.J.A.; Nieri, A.; Morbelli, S.; Erba, P.A.; Marini, C.; Strauss, H.W.; Sambuceti, G. Radionuclide imaging of cardiovascular disease.Nucl. Med. Textbook Methodol. Clin. Appl.Springer Nature Switzerland AG; , 2019, 2, pp. 449-497.
[http://dx.doi.org/10.1007/978-3-319-95564-3_20]
[12]
Simonen, P.; Lehtonen, J.; Kandolin, R.; Schildt, J.; Marjasuo, S.; Miettinen, H.; Airaksinen, J.; Vihinen, T.; Tuohinen, S.; Haataja, P.; Kupari, M. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am. J. Cardiol., 2015, 116(10), 1581-1585.
[http://dx.doi.org/10.1016/j.amjcard.2015.08.025] [PMID: 26411357]
[13]
Schneider, S.; Batrice, A.; Rischpler, C.; Eiber, M.; Ibrahim, T.; Nekolla, S.G. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur. Heart J., 2014, 35(5), 312.
[http://dx.doi.org/10.1093/eurheartj/eht335] [PMID: 23975480]
[14]
Dweck, M.R.; Abgral, R.; Trivieri, M.G.; Robson, P.M.; Karakatsanis, N.; Mani, V.; Palmisano, A.; Miller, M.A.; Lala, A.; Chang, H.L.; Sanz, J.; Contreras, J.; Narula, J.; Fuster, V.; Padilla, M.; Fayad, Z.A.; Kovacic, J.C. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc. Imaging, 2017, 9.
[PMID: 28624396]
[15]
Kim, S.J.; Pak, K.; Kim, K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis. J. Nucl. Cardiol., 2019, 2.
[http://dx.doi.org/10.1007/s12350-018-01582-y] [PMID: 30603894]
[16]
Chareonthaitawee, P.; Beanlands, R.S.; Chen, W.; Dorbala, S.; Miller, E.J.; Murthy, V.L.; Birnie, D.H.; Chen, E.S.; Cooper, L.T.; Tung, R.H.; White, E.S.; Borges-Neto, S.; Di Carli, M.F.; Gropler, R.J.; Ruddy, T.D.; Schindler, T.H.; Blankstein, R. Joint SNMMI-ASNC expert consensus document on the role of 18F-fdg PET/CT in cardiac sarcoid detection and therapy monitoring. J. Nucl. Med., 2017, 58(8), 1341-1353.
[http://dx.doi.org/10.2967/jnumed.117.196287] [PMID: 28765228]
[17]
Christopoulos, G.; Jouni, H.; Acharya, G.A.; Blauwet, L.A.; Kapa, S.; Bois, J.; Chareonthaitawee, P.; Rodriguez-Porcel, M.G. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol. J. Nucl. Cardiol., 2019, 20.
[http://dx.doi.org/10.1007/s12350-019-01746-4] [PMID: 31111450]
[18]
Bauckneht, M.; Ferrarazzo, G.; Fiz, F.; Morbelli, S.; Sarocchi, M.; Pastorino, F.; Ghidella, A.; Pomposelli, E.; Miglino, M.; Ameri, P.; Emionite, L.; Ticconi, F.; Arboscello, E.; Buschiazzo, A.; Massimelli, E.A.; Fiordoro, S.; Borra, A.; Cossu, V.; Bozzano, A.; Ibatici, A.; Ponzoni, M.; Spallarossa, P.; Gallamini, A.; Bruzzi, P.; Sambuceti, G.; Marini, C. Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational 18F-FDG PET/CT Observation. J. Nucl. Med., 2017, 58(10), 1638-1645.
[http://dx.doi.org/10.2967/jnumed.117.191122] [PMID: 28646013]
[19]
Sarocchi, M.; Bauckneht, M.; Arboscello, E.; Capitanio, S.; Marini, C.; Morbelli, S.; Miglino, M.; Congiu, A.G.; Ghigliotti, G.; Balbi, M.; Brunelli, C.; Sambuceti, G.; Ameri, P.; Spallarossa, P. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J. Transl. Med., 2018, 16(1), 295.
[http://dx.doi.org/10.1186/s12967-018-1670-9] [PMID: 30359253]
[20]
Bauckneht, M.; Morbelli, S.; Fiz, F.; Ferrarazzo, G.; Piva, R.; Nieri, A.; Sarocchi, M.; Spallarossa, P.; Canepari, M.E.; Arboscello, E.; Bellodi, A.; Massaia, M.; Gallamini, A.; Bruzzi, P.; Marini, C.; Sambuceti, G. A Score-based approach to 18F-FDG PET images as a tool to describe metabolic predictors of myocardial doxorubicin susceptibility. Diagnostics (Basel), 2017, 7(4), 57.
[http://dx.doi.org/10.3390/diagnostics7040057] [PMID: 29072629]
[21]
Bauckneht, M.; Pastorino, F.; Castellani, P.; Cossu, V.; Orengo, A.M.; Piccioli, P.; Emionite, L.; Capitanio, S.; Yosifov, N.; Bruno, S.; Lazzarini, E.; Ponzoni, M.; Ameri, P.; Rubartelli, A.; Ravera, S.; Morbelli, S.; Sambuceti, G.; Marini, C. Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress. J. Nucl. Cardiol., 2019.
[http://dx.doi.org/10.1007/s12350-019-01618-x] [PMID: 30737636]
[22]
Bauckneht, M.; Cossu, V.; Miceli, A.; Donegani, M.I.; Capitanio, S.; Morbelli, S.; Marini, C.; Sambuceti, G. FDG-PET imaging of doxorubicin-induced cardiotoxicity: a new window on an old problem. Curr. Cardiovasc. Imaging Rep., 2019, 12(41)
[http://dx.doi.org/10.1007/s12410-019-9517-1]
[23]
Anzola, L.K.; Glaudemans, A.W.J.M.; Dierckx, R.A.J.O.; Martinez, F.A.; Moreno, S.; Signore, A. Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(12), 2496-2513.
[http://dx.doi.org/10.1007/s00259-019-04489-z] [PMID: 31463594]
[24]
Oztürk, E.; Günalp, B.; Ozgüven, M.; Ozkan, S.; Sipit, T.; Narin, Y.; Bayhan, H. The visualization of granulomatous disease with somatostatin receptor scintigraphy. Clin. Nucl. Med., 1994, 19(2), 129-132.
[http://dx.doi.org/10.1097/00003072-199402000-00010] [PMID: 7910542]
[25]
Kwekkeboom, D.J.; Krenning, E.P.; Kho, G.S.; Breeman, W.A.P.; Van Hagen, P.M. Somatostatin receptor imaging in patients with sarcoidosis. Eur. J. Nucl. Med., 1998, 25(9), 1284-1292.
[http://dx.doi.org/10.1007/s002590050297] [PMID: 9724378]
[26]
Lebtahi, R.; Crestani, B.; Belmatoug, N.; Daou, D.; Delahaye, N.; Dombret, M.C.; Faraggi, M.; Aubier, M.; Le Guludec, D. Somatostatin receptor scintigraphy in patients with sarcoidosis: Comparison with gallium-67 scintigraphy. J. Nucl. Med., 1998, 39, 44.
[27]
Nobashi, T.; Nakamoto, Y.; Kubo, T.; Ishimori, T.; Handa, T.; Tanizawa, K.; Sano, K.; Mishima, M.; Togashi, K. The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy. Ann. Nucl. Med., 2016, 30(8), 544-552.
[http://dx.doi.org/10.1007/s12149-016-1095-6] [PMID: 27272495]
[28]
Reiter, T.; Werner, R.A.; Bauer, W.R.; Lapa, C. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur. Heart J., 2015, 36(35), 2404.
[http://dx.doi.org/10.1093/eurheartj/ehv278] [PMID: 26093640]
[29]
Lapa, C.; Reiter, T.; Kircher, M.; Schirbel, A.; Werner, R.A.; Pelzer, T.; Pizarro, C.; Skowasch, D.; Thomas, L.; Schlesinger-Irsch, U.; Thomas, D.; Bundschuh, R.A.; Bauer, W.R.; Gärtner, F.C. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget, 2016, 7(47), 77807-77814.
[http://dx.doi.org/10.18632/oncotarget.12799] [PMID: 27780922]
[30]
Pizarro, C.; Kluenker, F.; Dabir, D.; Thomas, D.; Gaertner, F.C.; Essler, M.; Grohé, C.; Nickenig, G.; Skowasch, D. Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis. ESC Heart Fail., 2018, 5(2), 249-261.
[http://dx.doi.org/10.1002/ehf2.12243] [PMID: 29231290]
[31]
Werner, R.A.; Weich, A.; Kircher, M.; Solnes, L.B.; Javadi, M.S.; Higuchi, T.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics, 2018, 8(22), 6088-6100.
[http://dx.doi.org/10.7150/thno.30357] [PMID: 30613284]
[32]
Laudicella, R.; Albano, D.; Annunziata, S.; Calabrò, D.; Argiroffi, G.; Abenavoli, E.; Linguanti, F.; Albano, D.; Vento, A.; Bruno, A.; Alongi, P.; Bauckneht, M. Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications. Cancers (Basel), 2019, 11(10), 1412.
[http://dx.doi.org/10.3390/cancers11101412] [PMID: 31546734]
[33]
Bravo, P.E.; Bajaj, N.; Padera, R.F.; Morgan, V.; Hainer, J.; Bibbo, C.F.; Harrington, M.; Park, M.A.; Hyun, H.; Robertson, M.; Lakdawala, N.K.; Groarke, J.; Stewart, G.C.; Dorbala, S.; Blankstein, R.; Di Carli, M.F. Feasibility of somatostatin receptor-targeted imaging for detection of myocardial inflammation: A pilot study. J. Nucl. Cardiol., 2019, 10, 1007.
[http://dx.doi.org/10.1007/s12350-019-01782-0] [PMID: 31197742]
[34]
Gormsen, L.C.; Haraldsen, A.; Kramer, S.; Dias, A.H.; Kim, W.Y.; Borghammer, P. A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res., 2016, 6(1), 52.
[http://dx.doi.org/10.1186/s13550-016-0207-6] [PMID: 27316444]
[35]
Lapa, C.; Reiter, T.; Li, X.; Werner, R.A.; Samnick, S.; Jahns, R.; Buck, A.K.; Ertl, G.; Bauer, W.R. Imaging of myocardial inflammation with somatostatin receptor based PET/CT - A comparison to cardiac MRI. Int. J. Cardiol., 2015, 194, 44-49.
[http://dx.doi.org/10.1016/j.ijcard.2015.05.073] [PMID: 26005805]
[36]
Zhao, S.; Kuge, Y.; Kohanawa, M.; Takahashi, T.; Zhao, Y.; Yi, M.; Kanegae, K.; Seki, K.; Tamaki, N. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT. J. Nucl. Med., 2008, 49(1), 135-141.
[http://dx.doi.org/10.2967/jnumed.107.044578] [PMID: 18077525]
[37]
Norikane, T.; Yamamoto, Y.; Maeda, Y.; Noma, T.; Nishiyama, Y. 18F-FLT PET imaging in a patient with sarcoidosis with cardiac involvement. Clin. Nucl. Med., 2015, 40(5), 433-434.
[http://dx.doi.org/10.1097/RLU.0000000000000653] [PMID: 25546198]
[38]
Norikane, T.; Yamamoto, Y.; Maeda, Y.; Noma, T.; Dobashi, H.; Nishiyama, Y. Comparative evaluation of 18F-FLT and 18F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res., 2017, 7(1), 69.
[http://dx.doi.org/10.1186/s13550-017-0321-0] [PMID: 28853043]
[39]
Martineau, P.; Pelletier-Galarneau, M.; Juneau, D.; Leung, E.; Nery, P.B.; de Kemp, R.; Beanlands, R.; Birnie, D. Imaging cardiac sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: a prospective pilot study. JACC Cardiovasc. Imaging, 2019, 12(11 Pt 1), 2280-2281.
[http://dx.doi.org/10.1016/j.jcmg.2019.06.020] [PMID: 31422126]
[40]
Hotta, M.; Minamimoto, R.; Kubota, S.; Awaya, T.; Hiroi, Y. 11C-4DST PET/CT imaging of cardiac sarcoidosis: comparison with 18F-FDG and cardiac MRI. Clin. Nucl. Med., 2018, 43(6), 458-459.
[http://dx.doi.org/10.1097/RLU.0000000000002059] [PMID: 29538030]
[41]
Piotrowski, W.J.; Kiszałkiewicz, J.; Pastuszak-Lewandoska, D.; Górski, P.; Antczak, A.; Migdalska-Sęk, M.; Górski, W.; Czarnecka, K.H.; Domańska, D.; Nawrot, E.; Brzeziańska-Lasota, E. Expression of HIF-1A/VEGF/ING-4 axis in pulmonary sarcoidosis. Adv. Exp. Med. Biol., 2015, 866, 61-69.
[http://dx.doi.org/10.1007/5584_2015_144] [PMID: 26022899]
[42]
Sato, J.; Kitagawa, Y.; Yamazaki, Y.; Hata, H.; Asaka, T.; Miyakoshi, M.; Okamoto, S.; Shiga, T.; Shindoh, M.; Kuge, Y.; Tamaki, N. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(11), 2031-2041.
[http://dx.doi.org/10.1007/s00259-014-2810-y] [PMID: 24867258]
[43]
Kiszałkiewicz, J.; Piotrowski, W.J.; Brzeziańska-Lasota, E. Selected molecular events in the pathogenesis of sarcoidosis - recent advances. Pneumonol. Alergol. Pol., 2015, 83(6), 462-475.
[http://dx.doi.org/10.5603/PiAP.2015.0076] [PMID: 26559800]
[44]
Manabe, O.; Hirata, K.; Shozo, O.; Shiga, T.; Uchiyama, Y.; Kobayashi, K.; Watanabe, S.; Toyonaga, T.; Kikuchi, H.; Oyama-Manabe, N.; Tamaki, N. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. J. Nucl. Cardiol., 2017, 24(1), 329-331.
[http://dx.doi.org/10.1007/s12350-016-0495-2] [PMID: 27071998]
[45]
Furuya, S.; Naya, M.; Manabe, O.; Hirata, K.; Ohira, H.; Aikawa, T.; Koyanagawa, K.; Magota, K.; Tsujino, I.; Anzai, T.; Kuge, Y.; Oyama-Manabe, N.; Kudo, K.; Shiga, T.; Tamaki, N. 18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. J. Nucl. Cardiol., 2019.
[http://dx.doi.org/10.1007/s12350-019-01976-6] [PMID: 31820409]
[46]
Kroenke, M.; Hirata, K.; Gafita, A.; Watanabe, S.; Okamoto, S.; Magota, K.; Shiga, T.; Kuge, Y.; Tamaki, N. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer. PLoS One, 2019, 14(2), e0213111.
[http://dx.doi.org/10.1371/journal.pone.0213111] [PMID: 30818360]
[47]
Korsten, P.; Tampe, B.; Konig, M.F.; Nikiphorou, E. Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. Curr. Opin. Pulm. Med., 2018, 24(5), 504-512.
[http://dx.doi.org/10.1097/MCP.0000000000000500] [PMID: 29985181]
[48]
Signore, A.; Anzola, K.L.; Auletta, S.; Varani, M.; Petitti, A.; Pacilio, M.; Galli, F.; Lauri, C. Current status of molecular imaging in inflammatory and autoimmune disorders. Curr. Pharm. Des., 2018, 24(7), 743-753.
[http://dx.doi.org/10.2174/1381612824666180130115153] [PMID: 29384051]

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy